Published on
03:52 GMT
FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns—including a case of serious liver injury that led to death. Dec. 24, …
Source:
Fierce Pharma
-
Neutral
